Rilotumumab Resistance Acquired by Intracrine Hepatocyte Growth Factor Signaling
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Rilotumumab Resistance Acquired by Intracrine Hepatocyte Growth Factor Signaling
Authors
Keywords
-
Journal
Cancers
Volume 15, Issue 2, Pages 460
Publisher
MDPI AG
Online
2023-01-11
DOI
10.3390/cancers15020460
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Caveolae-Associated Molecules, Tumor Stroma, and Cancer Drug Resistance: Current Findings and Future Perspectives
- (2022) Jin-Yih Low et al. Cancers
- Targeting Acquired and Intrinsic Resistance Mechanisms in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer
- (2022) Manan P. Shah et al. DRUGS
- Treatment Strategies and Outcomes for Patients with EGFR-mutant Non-Small Cell Lung Cancer Resistant to EGFR Tyrosine Kinase Inhibitors: Focus on Novel Therapies
- (2022) Melissa Johnson et al. LUNG CANCER
- Glioblastoma Treatment: State-of-the-Art and Future Perspectives
- (2022) Alejandro Rodríguez-Camacho et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Combination of HGF/MET-targeting agents and other therapeutic strategies in cancer
- (2021) Fatemeh Moosavi et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Exploring liver cancer biology through functional genetic screens
- (2021) Cun Wang et al. Nature Reviews Gastroenterology & Hepatology
- High-density lipoproteins and immune response: A review
- (2021) Elena Grao-Cruces et al. INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
- Pichia pastoris : A highly successful expression system for optimal synthesis of heterologous proteins
- (2020) Mohsen Karbalaei et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Safety and Tolerability of c-MET Inhibitors in Cancer
- (2019) Alberto Puccini et al. DRUG SAFETY
- Cellular origin of glioblastoma and its implication in precision therapy
- (2018) Maojin Yao et al. Cellular & Molecular Immunology
- Pharmacodynamic endpoints as clinical trial objectives to answer important questions in oncology drug development
- (2016) Ralph E. Parchment et al. SEMINARS IN ONCOLOGY
- Endoplasmic Reticulum Stress-Activated Cell Reprogramming in Oncogenesis
- (2015) E. Chevet et al. Cancer Discovery
- Identification of MET and SRC Activation in Melanoma Cell Lines Showing Primary Resistance to PLX4032
- (2015) Elisabetta Vergani et al. NEOPLASIA
- The Role of cMet in Non-Small Cell Lung Cancer Resistant to EGFRInhibitors: Did We Really Find the Target?
- (2014) Francesco Passiglia et al. CURRENT DRUG TARGETS
- Processed pseudogenes acquired somatically during cancer development
- (2014) Susanna L. Cooke et al. Nature Communications
- Characterization of a Novel PERK Kinase Inhibitor with Antitumor and Antiangiogenic Activity
- (2013) C. Atkins et al. CANCER RESEARCH
- The Somatic Genomic Landscape of Glioblastoma
- (2013) Cameron W. Brennan et al. CELL
- Microdomains in the membrane landscape shape antigen-presenting cell function
- (2013) Malou Zuidscherwoude et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
- (2013) J. Gao et al. Science Signaling
- An Orally Bioavailable c-Met Kinase Inhibitor Potently Inhibits Brain Tumor Malignancy and Growth
- (2012) Fadila Guessous et al. Anti-Cancer Agents in Medicinal Chemistry
- Lipid-dependent protein sorting at the trans-Golgi network
- (2012) Michal A. Surma et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS
- Targeted Disruption of Heparan Sulfate Interaction with Hepatocyte and Vascular Endothelial Growth Factors Blocks Normal and Oncogenic Signaling
- (2012) Fabiola Cecchi et al. CANCER CELL
- The MET Oncogene Is a Functional Marker of a Glioblastoma Stem Cell Subtype
- (2012) F. De Bacco et al. CANCER RESEARCH
- MET Activation Mediates Resistance to Lapatinib Inhibition of HER2-Amplified Gastric Cancer Cells
- (2012) C.-T. Chen et al. MOLECULAR CANCER THERAPEUTICS
- Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
- (2012) Ravid Straussman et al. NATURE
- Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
- (2012) Timothy R. Wilson et al. NATURE
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.
- (2012) Ethan Cerami et al. Cancer Discovery
- Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma
- (2011) Inna V. Fedorenko et al. BIOCHEMICAL PHARMACOLOGY
- Hedgehog Fights Back: Mechanisms of Acquired Resistance against Smoothened Antagonists
- (2011) C. Metcalfe et al. CANCER RESEARCH
- c-Met inhibitors with different binding modes: Two is better than one
- (2011) Isabelle Dussault et al. CELL CYCLE
- Hepatocyte Growth Factor Expression in EGFR Mutant Lung Cancer with Intrinsic and Acquired Resistance to Tyrosine Kinase Inhibitors in a Japanese Cohort
- (2011) Seiji Yano et al. Journal of Thoracic Oncology
- Hepatocyte Growth Factor Induces Resistance to Anti-Epidermal Growth Factor Receptor Antibody in Lung Cancer
- (2011) Tadaaki Yamada et al. Journal of Thoracic Oncology
- EGFR and MET receptor tyrosine kinase–altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers
- (2011) Michela Garofalo et al. NATURE MEDICINE
- Treatment of HER2-positive breast cancer: current status and future perspectives
- (2011) Carlos L. Arteaga et al. Nature Reviews Clinical Oncology
- Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma
- (2011) Q. Xie et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC
- (2010) Alexa B. Turke et al. CANCER CELL
- Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1
- (2010) Roel G.W. Verhaak et al. CANCER CELL
- Safety, Pharmacokinetics, and Pharmacodynamics of AMG 102, a Fully Human Hepatocyte Growth Factor-Neutralizing Monoclonal Antibody, in a First-in-Human Study of Patients with Advanced Solid Tumors
- (2010) M. S. Gordon et al. CLINICAL CANCER RESEARCH
- Reciprocal and Complementary Role of MET Amplification and EGFR T790M Mutation in Acquired Resistance to Kinase Inhibitors in Lung Cancer
- (2010) K. Suda et al. CLINICAL CANCER RESEARCH
- Radiosensitization of glioma cells by modulation of Met signalling with the hepatocyte growth factor neutralizing antibody, AMG102
- (2010) Ian M. Buchanan et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Biochemical Characterization of AMG 102: A Neutralizing, Fully Human Monoclonal Antibody to Human and Nonhuman Primate Hepatocyte Growth Factor
- (2010) T. L. Burgess et al. MOLECULAR CANCER THERAPEUTICS
- Molecular mechanisms of the origin of micronuclei from extrachromosomal elements
- (2010) N. Shimizu MUTAGENESIS
- A coding-independent function of gene and pseudogene mRNAs regulates tumour biology
- (2010) Laura Poliseno et al. NATURE
- Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors
- (2009) Alessandro A. Boezio et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Beyond Trastuzumab: Overcoming Resistance to Targeted HER-2 Therapy in Breast Cancer
- (2009) Philippe Bedard et al. CURRENT CANCER DRUG TARGETS
- Somatic mutation and functional polymorphism of a novel regulatory element in the HGF gene promoter causes its aberrant expression in human breast cancer
- (2009) Jihong Ma et al. JOURNAL OF CLINICAL INVESTIGATION
- Hepatocyte growth factor in cerebrospinal fluid is associated with mortality and recurrence of glioblastoma, and could be of prognostic value
- (2009) Roberto Garcia-Navarrete et al. JOURNAL OF NEURO-ONCOLOGY
- Therapeutic potential of hepatocyte growth factor/scatter factor neutralizing antibodies: Inhibition of tumor growth in both autocrine and paracrine hepatocyte growth factor/scatter factor:c-Met-driven models of leiomyosarcoma
- (2009) C.-F. Gao et al. MOLECULAR CANCER THERAPEUTICS
- MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients
- (2008) F. Cappuzzo et al. ANNALS OF ONCOLOGY
- Met Receptor Contributes to Trastuzumab Resistance of Her2-Overexpressing Breast Cancer Cells
- (2008) D. L. Shattuck et al. CANCER RESEARCH
- Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor-Activating Mutations
- (2008) S. Yano et al. CANCER RESEARCH
- Comprehensive genomic characterization defines human glioblastoma genes and core pathways
- (2008) Roger McLendon et al. NATURE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search